Lunchtime announcement: Yuheng Pharmaceutical intends to sign an agreement to resolve the debt dispute related to the transfer of equity of Yuheng Biology.

1) Yuheng Pharmaceutical: The company plans to resolve the debt dispute between the company and Qingdao Pusheng Publishing Enterprise Management Center regarding the equity transfer payment of Guangzhou Yuheng Biological Technology Co., Ltd. by signing an agreement. As Pusheng Publishing failed to pay the equity transfer payment of 117.6 million yuan for purchasing 42.12% equity of Yuheng Biological within the agreed time, the company filed a lawsuit in April 2024. As of now, the lawsuit has entered the enforcement stage, and the company has not received the related payment. Pusheng Publishing plans to transfer the 20.64% equity of Yuheng Biological to Youpeng Biological Technology Co., Ltd., and use the related payment to repay the debt owed by Pusheng Publishing to the company. The company, Pusheng Publishing, Youpeng Biological, and Yuheng Biological plan to jointly sign an agreement, in which it is stipulated that Pusheng Publishing will transfer the 20.64% equity of Yuheng Biological to Youpeng Biological, and Pusheng Publishing will use the proceeds to repay the debt dispute of the equity transfer to the company. 2) New Taike: November 4th is the last conversion date for "New Taike Convertible Bonds". Investors holding "New Taike Convertible Bonds" can still convert them before the market closes on November 4th. After the market closes on November 4th, any "New Taike Convertible Bonds" that have not been converted will stop converting, and the remaining "New Taike Convertible Bonds" will be forcibly redeemed at a price of 100.36 yuan per bond. If forcibly redeemed, investors may incur losses.